Resmetirom Shows Potential in Combating Liver Cancer Linked to Fatty Liver Disease
A recent study has revealed that Resmetirom, a drug approved by the U.S. Food and Drug Administration (FDA) for treating metabolic dysfunction associated fatty liver disease (MAFLD), may also help prevent and suppress liver cancer. Conducted by researchers from the University of Hong Kong, the study found that Resmetirom not only reduces liver fat but also slows tumor growth and lowers levels of the Midkine (MDK) protein, which is linked to cancer progression. The study highlights the potential of Resmetirom in reshaping the immune microenvironment and improving liver metabolism, suggesting its clinical value in future treatment strategies for liver cancer. 
